Q1 FY27 results: PAT up 27%, revenue up 19%, INR 5 interim dividend

Pat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemResults View source PDF

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+7.7%1-day move

₹1690.10

prior close

₹1671.10

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.7+1.1+1.3+2.1+7.7—————————

Up moveDown movePending

AI summary

Dr. Lal PathLabs Q1 FY27: consolidated revenue INR 7,977M (up 19% YoY), PAT INR 1,705M (up 27% YoY), EPS INR 10.15. Board declared INR 5 per share interim dividend (record date July 30). Completed acquisition of Shahbazkers Diagnostic (INR 200M) and approved 80% stake in Sunshine Healthcare Ghana (up to INR 380M) and 30% in Neuome Technologies (up to INR 35M). Auditor Deloitte gave unmodified conclusion.

Likely market impact

Strong Q1 with PAT growth of 27% and margin expansion. Interim dividend plus acquisitions in India and Ghana signal growth push.